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Purpose of the study
As a chemokine coreceptor antagonist, maraviroc
(MVC) inhibits HIV infection by preventing viral entry
into the host cell. As this effect is extracellular, we
hypothesized that virus might be returned to plasma
upon antagonism of CCR5 by MVC and that this
thereby influences measurement of plasma viral load by
qRT-PCR, in contrast to other drug classes that act
intracellularly.
Methods
PM-1 and TZM/bl cells were infected with titrations of
a CCR5 tropic reference virus in the presence of inhibi-
tory concentrations of MVC (500nM), efavirenz (EFV)
(500nm), and raltegravir (RAL) (1µM). Viral inoculation
varied between 10
4-10
7 copies of viral RNA/ml. Cells
were centrifuged and supernatant viral load was mea-
s u r e db yq R T - P C Rf o rv i r a lR N Aa tv a r i o u st i m e sf r o m
shortly after infection through 48 hours after infection.
Summary of results
At the highest inoculum used, the amounts of viral RNA
detected in culture supernatants following treatment
w i t hM V Cw e r ec o n s i s t e n t l yh i g h e rb y~0 . 5l o gc o p i e s
HIV-1 RNA/ml than found with untreated cells despite
no detectable infection in the presence of MVC as
revealed by production of p24 Ag in the case of PM-1
cells and expression of luciferase in the case of TZM/bl
cells. At lower levels of inoculum, the results were con-
sistent although less striking, but there was always a sig-
nificant difference in regard to the use of MVC versus
other drugs. In contrast, the results obtained with EFV
and RAL resembled those obtained in the absence of
drug, despite no detectable infection.
Conclusions
These results suggest in a tissue culture model that
MVC can return virus to plasma, where it may contri-
bute to viral load despite complete inhibition of infec-
tion. In contrast, for drugs that act at an intracellular
level, cells can absorb residual virus before such virus it
is inhibited by the compound. Consequently, such virus
will not contribute to viral load. In view of the fact that
viral production by infected cells is an ongoing process,
these findings imply that the true effectiveness of MVC
is currently underestimated when viral load is used as a
sole indicator of clinical success. These data may also be
relevant for other classes of entry inhibitors.
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